

# Stefano Maria Santini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6023052/publications.pdf>

Version: 2024-02-01

35  
papers

2,252  
citations

393982

19  
h-index

377514

34  
g-index

37  
all docs

37  
docs citations

37  
times ranked

2445  
citing authors

#	ARTICLE	IF	CITATIONS
1	Type I IFN-dependent antibody response at the basis of sex dimorphism in the outcome of COVID-19. Cytokine and Growth Factor Reviews, 2021, 58, 66-74.	3.2	14
2	IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives. Vaccines, 2020, 8, 617.	2.1	14
3	Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma. Cancer Immunology, Immunotherapy, 2020, 69, 913-925.	2.0	7
4	INTRANODAL TREATMENT WITH IFN $\hat{I}$ -DENDRITIC CELLS AND RITUXIMAB INDUCES SYSTEMIC CLINICAL RESPONSE AND ENDOGENOUS VACCINATION AGAINST FOLLICULAR LYMPHOMA: FINAL RESULT OF A PHASE I STUDY. Hematological Oncology, 2019, 37, 317-318.	0.8	0
5	Lenalidomide improves the therapeutic effect of an interferon- $\hat{I}$ -dendritic cell-based lymphoma vaccine. Cancer Immunology, Immunotherapy, 2019, 68, 1791-1804.	2.0	18
6	Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFN $\hat{I}$ -Dendritic Cells and Rituximab: a Phase I Clinical Trial. Clinical Cancer Research, 2019, 25, 5231-5241.	3.2	34
7	NK Cell Activation in the Antitumor Response Induced by IFN- $\hat{I}$ Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients. Journal of Immunology, 2016, 197, 795-806.	0.4	19
8	Personalized Immunotherapy in Follicular Lymphoma By Intranodal IFN-Dendritic-Cell Combined to Anti-CD20 Antibody. Blood, 2016, 128, 2976-2976.	0.6	5
9	IFN- $\hat{I}$ enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood, 2012, 119, 1407-1417.	0.6	119
10	Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. Vaccine, 2011, 29, 3465-3475.	1.7	17
11	Interferon- $\hat{I}$ -Conditioned Human Monocytes Combine a Th1-Orienting Attitude with the Induction of Autologous Th17 Responses: Role of IL-23 and IL-12. PLoS ONE, 2011, 6, e17364.	1.1	60
12	Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology, 2009, 395, 45-55.	1.1	39
13	IFN-alpha in the Generation of Dendritic Cells for Cancer Immunotherapy. Handbook of Experimental Pharmacology, 2009, , 295-317.	0.9	53
14	Differentiation of monocyte-derived dendritic cells is associated with upregulation and activation of Rac-1 small GTPase. FEBS Letters, 2006, 580, 3335-3339.	1.3	4
15	IFN- $\hat{I}$ -conditioned dendritic cells are highly efficient in inducing cross-priming CD8+ T cells against exogenous viral antigens. European Journal of Immunology, 2006, 36, 2046-2060.	1.6	132
16	Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice. International Immunology, 2005, 17, 469-475.	1.8	22
17	Type I Interferons as Regulators of the Differentiation/Activation of Human Dendritic Cells. , 2005, 116, 167-181.		12
18	CD2+/CD14+ monocytes rapidly differentiate into CD83+ dendritic cells. European Journal of Immunology, 2003, 33, 358-367.	1.6	26

#	ARTICLE	IF	CITATIONS
19	Potent Immune Response against HIV-1 and Protection from Virus Challenge in hu-PBL-SCID Mice Immunized with Inactivated Virus-pulsed Dendritic Cells Generated in the Presence of IFN- $\gamma$ . <i>Journal of Experimental Medicine</i> , 2003, 198, 361-367.	4.2	130
20	The Natural Alliance Between Type I Interferon and Dendritic Cells and Its Role in Linking Innate and Adaptive Immunity. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 1071-1080.	0.5	77
21	Expression of CCR-7, MIP-3 $\beta$ , and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. <i>Blood</i> , 2001, 98, 3022-3029.	0.6	231
22	Primary HIV-1 infection of human CD4 <sup>+</sup> T cells passaged into SCID mice leads to selection of chronically infected cells through a massive Fas-mediated autocrine suicide of uninfected cells. <i>Cell Death and Differentiation</i> , 2000, 7, 37-47.	5.0	12
23	Cyclophosphamide induces type I interferon and augments the number of CD44 <sup>hi</sup> T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. <i>Blood</i> , 2000, 95, 2024-2030.	0.6	189
24	Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice. <i>Journal of Experimental Medicine</i> , 2000, 191, 1777-1788.	4.2	590
25	Murine interferon- $\gamma$ gene-transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to interferon- $\gamma$ therapy. <i>Cancer Gene Therapy</i> , 1999, 6, 246-253.	2.2	9
26	Type I Interferon Is a Powerful Inhibitor of in Vivo HIV-1 Infection and Preserves Human CD4 <sup>+</sup> T Cells from Virus-Induced Depletion in SCID Mice Transplanted with Human Cells. <i>Virology</i> , 1999, 263, 78-88.	1.1	57
27	Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. <i>European Journal of Immunology</i> , 1999, 29, 1202-1208.	1.6	120
28	Human Immunodeficiency Virus Type 1 Strains R5 and X4 Induce Different Pathogenic Effects in hu-PBL-SCID Mice, Depending on the State of Activation/Differentiation of Human Target Cells at the Time of Primary Infection. <i>Journal of Virology</i> , 1999, 73, 6453-6459.	1.5	43
29	Role of Cytokines in GVL (ESb Lymphoma) and GVHD After Adoptive Transfer of Allogeneic T Lymphocytes in Mice. <i>Journal of Interferon and Cytokine Research</i> , 1998, 18, 667-679.	0.5	3
30	TREATMENT OF SEVERE COMBINED IMMUNODEFICIENCY MICE WITH ANTI-MURINE GRANULOCYTE MONOCLONAL ANTIBODY IMPROVES HUMAN LEUKOCYTE XENOTRANSPLANTATION1. <i>Transplantation</i> , 1998, 65, 416-420.	0.5	17
31	Human Lymphoblastoid CD4 <sup>+</sup> T Cells Become Permissive to Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 after Passage into Severe Combined Immunodeficient Mice through In Vivo Upregulation of CCR5: In Vivo Dynamics of CD4 <sup>+</sup> T-Cell Differentiation in Pathogenesis of AIDS. <i>Journal of Virology</i> , 1998, 72, 10323-10327.	1.5	12
32	U937-SCID mouse xenografts: a new model for acute in vivo HIV-1 infection suitable to test antiviral strategies. <i>Antiviral Research</i> , 1997, 36, 81-90.	1.9	19
33	T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: in vivo effects of HIV on highly activated human immune cells. <i>Journal of Virology</i> , 1996, 70, 7958-7964.	1.5	49
34	HIV Type 1 Grown on Interferon $\beta$ -Treated U937 Cells Shows Selective Increase in Virion-Associated Intercellular Adhesion Molecule 1 and HLA-DR and Enhanced Infectivity for CD4-Negative Cells. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 547-553.	0.5	55
35	THE SCID MOUSE REACTION TO HUMAN PERIPHERAL BLOOD MONONUCLEAR LEUKOCYTE ENGRAFTMENT. <i>Transplantation</i> , 1995, 60, 1306-1313.	0.5	18